Recent studies have focused on the overlap of glucagon-like peptide-1|GIP|glucagon receptor stimulant therapies and DA neurotransmission. While GIP activators are widely employed for managing type 2 T2DM, their unexpected consequences on reinforcement circuits, specifically governed by dopamine s